Searchable abstracts of presentations at key conferences in endocrinology

ea0029p810 | Endocrine tumours and neoplasia | ICEECE2012

Looking for the molecular bridge between sex hormone-binding globulin (SHBG) and breast cancer cells

Marano F. , Catalano M. , Frairia R. , Boccuzzi G. , Fortunati N.

Sex Hormone-Binding Globulin (SHBG), the specific plasma carrier for sex steroids, interacts with cell membranes. In breast cancer cells, SHBG-cell interaction is closely related to estrogen-sensitivity and it is followed by a well-defined cascade of events. Soon after SHBG binding to cell membranes, cAMP accumulates in the breast cancer cells, activates PKA that in turn suppresses estradiol-induced ERK activation. ERK inhibition abolishes the anti-apoptotic effects of estradi...

ea0098c30 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Novel alternate (Alt) response criteria for early outcome prediction in pancreatic (P) neuroendocrine tumors (NETs): utilizing banked imaging and radiomics

Lareef Ishara , Vijayvergia Namrata , Handorf Elizabeth , Kunz Pamela L. , Alkim Emil , Burke Lauren M. , Catalano Paul , Graham Noah , Levin Laura , Li Weier , Meeker Caitlin , Rubin Daniel , Sridharan Anush , O'Dwyer Peter J. , Wong Terence Z. , Anaokar Jordan

Background: Evaluating treatment (Tx) Response in NETs using CT/MRI scans can be difficult. Previous studies, including the E2211, have shown improved progression-free survival (PFS) but no significant difference in Rp as measured by RECIST 1.1 (R1.1) criteria. Therefore, it is difficult to determine Tx effectiveness with short-term imaging, further complicated by differences in imaging protocols and inter-reader variability. Incorporating tumor density, using smaller threshol...